Category Archives: Recent News

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 ...

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s ...

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

ABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 ...

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data 55% of BriaCell patients[1] ...

BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – October 1, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with ...

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in ...

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with ...